Product Description
A recombinant immunoglobulin G1 (IgG1) monoclonal antibody directed against the epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Upon administration, modotuximab targets and binds to an epitope located in the extracellular domain (ECD) of EGFR, which causes internalization and degradation of EGFR, including the mutated EGFR variant III (EGFRvIII). This prevents EGFR-mediated signaling, thereby inhibition EGFR-dependent tumor cell proliferation. EGFR, a receptor tyrosine kinase, often is overexpressed on the cell surfaces of various solid tumor cell types. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/modotuximab)
Mechanisms of Action: EGFR Binder
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Symphogen A/S
Company Location: Europe
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Belgium, Denmark, Finland, United States
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Colorectal Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2021-003151-41 |
COLSTAR | P3 |
Active, not recruiting |
Colorectal Cancer |
2026-10-25 |
2022-03-13 |
Treatments |
|
jRCT2031210653 |
jRCT2031210653 | P3 |
Active, not recruiting |
Colorectal Cancer |
2026-08-31 |
Recent News Events
Date |
Type |
Title |
|---|